The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Yue,Pan ^[1] ; Chao,Deng ^[1] ; Zhenhua,Qiu ^[1] ; Chenghui,Cao ^[2] ; Fang,Wu ^[1]

作者单位： Department of Oncology, Second Xiangya Hospital, Central South University, Changsha, China. ^[1] Central South University, Changsha, China. ^[2] Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, China. ^[3] Hunan Key Laboratory of Tumor Models and Individualized Medicine, Second Xiangya Hospital, Central South University, Changsha, China. ^[4] Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital, Central South University, Changsha, China. ^[5]

关键词 NSCLC TKI - tyrosine kinase inhibitor anaplastic lymphoma kinase (ALK)resistance therapy

DOI 10.3389/fonc.2021.713530

PMID 34660278

发布时间 2021-10-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2021年11卷

713530页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除